Earnings analysis · 10-Q
ILMN earnings analysis
Filed May 1, 2026 · Our reading of the company's report
The latest report
Illumina, Inc. reported Q1 2026 revenue of $1.09 billion, marking a slight increase from the previous quarter's revenue of $1.04 billion and surpassing estimates. The company also reported GAAP diluted EPS of $1.15,…
Read full summary
Illumina, Inc. reported Q1 2026 revenue of $1.09 billion, marking a slight increase from the previous quarter's revenue of $1.04 billion and surpassing estimates. The company also reported GAAP diluted EPS of $1.15, exceeding analysts' expectations and reflecting a strong performance driven by continued demand for its genomic products.
Reported figures
- Earnings per share
- $1.15
What stood out
-
Revenue Beat Estimates
Actual revenue was $1.09 billion, beating estimates of $1.07 billion by 1.4%.
-
Strong EPS Result
Reported EPS was $1.15, exceeding the expected $1.05 by 9.5%.
-
Improved Free Cash Flow
Free cash flow for the quarter improved to $219 million.
-
Positive Segment Trends
Segments related to genomic research and clinical oncology showed solid growth.
-
Guidance Raised
Full-year revenue guidance adjusted to $4.52B-$4.62B, an increase of $20 million.
-
Continued Demand Growth
Management highlighted strong ongoing demand, particularly in the genomic sequencing market.
What to watch
-
Cost Implications
Increased costs related to R&D could impact margins.
-
Regulatory Uncertainty
Ongoing regulatory changes in the genomic and healthcare sectors pose risks.
-
Integration Risks
Challenges could arise from ongoing integration of new technologies.
Management's outlook
Revenue guidance raised by $20 million at the midpoint and EPS guidance increased to $5.15-$5.30.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.